Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer

Ovarian cancer is the most lethal malignant tumor of female reproductive system. It is well-known that induction of STING-mediated type I interferons can enhance the resultant antitumor activity. However, STING pathway is usually inactivated in cancer cells at multiple levels. Here, we identified deubiquitinase USP35 is upregulated in ovarian cancer tissues. High level of USP35 was correlated with diminished CD8(+)T cell infiltration and poor prognosis in ovarian cancer patients. Mechanistically, we found that silencing USP35 reinforces the activation of STING-TBK1-IRF3 pathway and promotes the expression of type I interferons. Our data further showed that USP35 can directly deubiquitinate and inactivate STING. Interestingly, activation of STING promotes its binding to USP35 in a STING phosphorylation-dependent manner. Functionally, we found that knockdown of USP35 sensitizes ovarian cancer cells to the DNA-damage chemotherapeutic drug cisplatin. Overall, our study indicates that upregulation of USP35 may be a mechanism of the restricted STING activity in cancer cells, and highlights the significance of USP35 as a potential therapeutic target for ovarian cancer.

Automated summary

The study identified that elevated USP35 levels in ovarian cancer correlate with reduced CD8(+) T cell infiltration and poor prognosis in patients. Silencing USP35 enhances STING activity, increases type I interferon expression, and directly deubiquitinates and inactivates STING. Furthermore, USP35 sensitizes ovarian cancer cells to DNA-damage chemotherapeutic drug cisplatin, suggesting its potential as a therapeutic target for ovarian cancer.